<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001272</url>
  </required_header>
  <id_info>
    <org_study_id>2012-772</org_study_id>
    <nct_id>NCT02001272</nct_id>
  </id_info>
  <brief_title>EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer</brief_title>
  <acronym>EWOC-1</acronym>
  <official_title>EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of first-line chemotherapy in advanced ovarian cancer is the combination&#xD;
      of carboplatin AUC 5mg/mL/min and paclitaxel 175 mg.m-². This combination is feasible in&#xD;
      selected elderly patients such as those included in prospective trials. These trials,&#xD;
      however, include a minority of the elderly population. In wider selection of patients &gt;70&#xD;
      years old, the standard carboplatin-paclitaxel regimen has been shown to induce an excess of&#xD;
      toxicity and premature treatment stopping. For elderly patients thought to be vulnerable and&#xD;
      at high risk of toxicity with the standard 3-weekly carboplatin-paclitaxel regimen, other&#xD;
      options are used in routine practice. One option is to delete paclitaxel and treat elderly&#xD;
      patients with carboplatin as a single agent. An alternative is to use the&#xD;
      carboplatin-paclitaxel regimen in a weekly schedule for both drugs such as reported by the&#xD;
      MITO (Multicentre Italian Trial in Ovarian Cancer).&#xD;
&#xD;
      To date, there is no randomized trial which could give us some evidence of how to select&#xD;
      patients who could benefit most of one or the other regimen described above. The 4th Ovarian&#xD;
      Cancer Consensus Conference has indeed recognised the medical unmet need of adapted therapy&#xD;
      for elderly patients with ovarian cancer and the necessity of additional research in this&#xD;
      population.&#xD;
&#xD;
      Recently, GINECO has described a Geriatric Vulnerability Score (GVS) in a population of&#xD;
      elderly patients with advanced ovarian cancer included in a specific multicenter phase II&#xD;
      trial. The best proportional hazard model fitting for overall survival identified the&#xD;
      following geriatric covariates score as being poor survival risk factors: ADL score &lt;6, IADL&#xD;
      score &lt;25, HADS score &gt;14, albuminemia &lt;35g/L and , lymphopenia &lt;1G/L. GVS is the sum of&#xD;
      these risk factors for each patient. Using a cut off of 3, the GVS identified a group of&#xD;
      patients at high risk of severe toxicity, early cessation of treatment, unplanned&#xD;
      hospitalization and adverse outcomes.&#xD;
&#xD;
      This international multicentre randomized phase II trial will compare the success rate of&#xD;
      delivering 6 courses of chemotherapy with evidence of efficacy and without premature&#xD;
      termination for progression, death or unacceptable toxicity of three different chemotherapy&#xD;
      regimens in a selected population of elderly patients with a GVS ≥ 3:&#xD;
&#xD;
        -  Arm A: Paclitaxel 175mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks&#xD;
&#xD;
        -  Arm B: Carboplatin monotherapy AUC 5 or 6 every 3 weeks&#xD;
&#xD;
        -  Arm C: Weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 every&#xD;
           4 weeks)&#xD;
&#xD;
      The total number of patients to be enrolled is 240, ie 22 in each arm (total = 66) at the&#xD;
      first step, then 58 more by arm (total=174) after interim analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success.Treatment success is defined as the ability to deliver 6 courses of chemotherapy without premature termination for progression, death or unacceptable toxicity</measure>
    <time_frame>After 6 courses of chemotherapy i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Treatment success is defined as the ability to deliver 6 courses of chemotherapy without premature termination for progression, death or unacceptable toxicity. Unacceptable toxicity is defined as a major adverse event related to chemotherapy or treatment procedure leading either to early treatment stopping, to an unplanned hospital admission or to death or to a dose delay lasting more than 14 days or more than 2 dose reductions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutical strategy</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Therapeutical strategy will be assessed by measuring the feasibility of performing an optimal surgery and feasibility of performing neoadjuvant chemotherapy and surgery and post operative chemotherapy until 6 courses in case of planned interval debulking surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2.5 years</time_frame>
    <description>Overall survival is defined as the time period from the date of randomization to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2.5 years</time_frame>
    <description>Progression-free survival is defined as the time period from the date of randomization to the date of disease progression or death whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Quality of life is evaluated using the FACT-O questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Adverse events are defined using the NCI-CTC AE scale version 4.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging biomarkers</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Aging biomarkers are represented by the expression level of cathelin-related antimicrobial peptide or CRAMP, stathmin, EF-1α, and chitinase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>A:Paclitaxel + Carboplatin every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B:Carboplatin monotherapy every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C:Weekly Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Carboplatin every 3 weeks</intervention_name>
    <description>Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.</description>
    <arm_group_label>A:Paclitaxel + Carboplatin every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin monotherapy every 3 weeks</intervention_name>
    <description>A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.</description>
    <arm_group_label>B:Carboplatin monotherapy every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Weekly Paclitaxel and Carboplatin</intervention_name>
    <description>A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.</description>
    <arm_group_label>C:Weekly Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman &gt;70 year old&#xD;
&#xD;
          -  Histologically or cytologically proven FIGO stage III to IV epithelial ovarian cancer&#xD;
             or peritoneal primary or fallopian tube. A cytological proof is accepted if associated&#xD;
             with a ratio of CA125/CEA &gt;25 and a radiological pelvic mass.&#xD;
&#xD;
          -  GVS (Geriatric Vulnerability Score) &gt;3.&#xD;
&#xD;
          -  Adequate bone marrow function including the following: Neutrophils ≥ 1.5 x 109/L ,&#xD;
             platelets ≥100 x 109/L and hemoglobin ≥9 g/dL.&#xD;
&#xD;
          -  Adequate glomerular filtration rate &gt;40 ml/min (estimates based on MDRD or Chatelut&#xD;
             formula are sufficient)&#xD;
&#xD;
          -  No icterus.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
          -  Covered by a Health System where applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in&#xD;
             situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited&#xD;
             basal cell skin cancer.&#xD;
&#xD;
          -  Prior history of chemotherapy.&#xD;
&#xD;
          -  Prior history of radiotherapy which may affect patient tolerability to chemotherapy.&#xD;
&#xD;
          -  Major perturbations of liver biology: Bilirubin &gt; 2 fold the upper normal limit (UNL),&#xD;
             SGOT-SGPT &gt; 3 fold UNL.&#xD;
&#xD;
          -  Patient unable to be regularly followed for any reason (geographic, familial, social,&#xD;
             psychologic).&#xD;
&#xD;
          -  Any mental or physical handicap at risk of interfering with the appropriate treatment.&#xD;
&#xD;
          -  Known allergy to Cremophor ® EL -containing drugs.&#xD;
&#xD;
          -  Any administrative or legal supervision where applicable&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire FALANDRY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'oncogériatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Notre-Dame Hospital of the CHUM</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier d'Alès</name>
      <address>
        <city>Alès</city>
        <zip>30100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de cancérologie clinique - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Bergonié</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Onco-Hématologie - Hôpital Fleyriat</name>
      <address>
        <city>Bourg en Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Radiothérapie et Oncologie Médicale - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Uro-Gynécologie - Centre François Baclesse</name>
      <address>
        <city>Caen Cedex 5</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Centre Hospitalier de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Centre Hospitalier Alpes Leman</name>
      <address>
        <city>Contamines Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Radiothérapie - Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre d'Oncologie et de Radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Gériatrique - Centre Hospitalier Intercommunal des Alpes du Sud -Site de Gap</name>
      <address>
        <city>Gap</city>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital Michallon - CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d''Hématologie Oncologie - Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Jean Bernard - Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne et Oncologie Médicale - CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Service 2 B Nord - Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie multidisciplinaire - Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Régional du Cancer Montpellier, Val d'Aurelle</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins Cedex 02</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chimiothérapie - Centre Catherine de Sienne</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Onco-Hématologie - Centre Antoine Lacassagne</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06186</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Radiothérapie - Clinique de Valdegour</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicde d'Oncologie Médicale - Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans Cedex 02</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital des Diaconesses</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Hôpital Cochin</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Groupe Hospitalier Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service oncogériatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - Hôpital Privé des Côtes d'Armor</name>
      <address>
        <city>Plerin Sur Mer</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Centre Hospitalier de la Région d'Annecy</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servide de Radiothérapie et Oncologie Médicale - Centre Hospitalier Intercommunal de Cornouaille</name>
      <address>
        <city>Quimper Cedex</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Institut Jean Godinot</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier Yves le Foll</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - ICO Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>service d'Oncologie Médicale - Centre Hospitalier Broussais</name>
      <address>
        <city>Saint Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne et oncologie - Hôpital Inter Armées de Begin</name>
      <address>
        <city>Saint Mandé</city>
        <zip>94163</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Clinique Mutualiste de l'Estuaire, Cité Sanitaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Radiothérapie - Centre Hospitalier Privé de Saint-Grégoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Groupe Hospitalier Public du Sud de l'Oise - Site de Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier de Sens</name>
      <address>
        <city>Sens</city>
        <zip>89108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie et Oncologie Gynécologique et Mammaire - Hôpitaux du Léman</name>
      <address>
        <city>Thonon les Bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Oncologique - Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - CRO,IRCCS</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ulss 21 Legnago</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulls13 - Mirano</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuovo di Sassuolo</name>
      <address>
        <city>Sassuolo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - Istituto di Candiolo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.arcagy.org</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.esgo.org/engot/Pages/AboutENGOT.aspx</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Vulnerable</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

